CA2342773A1 - Interferon-epsilon - Google Patents

Interferon-epsilon Download PDF

Info

Publication number
CA2342773A1
CA2342773A1 CA002342773A CA2342773A CA2342773A1 CA 2342773 A1 CA2342773 A1 CA 2342773A1 CA 002342773 A CA002342773 A CA 002342773A CA 2342773 A CA2342773 A CA 2342773A CA 2342773 A1 CA2342773 A1 CA 2342773A1
Authority
CA
Canada
Prior art keywords
interferon
amino acid
seq
acid residues
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002342773A
Other languages
English (en)
French (fr)
Inventor
Darrell C. Conklin
Francis J. Grant
Mark Rixon
Wayne Kindsvogel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2342773A1 publication Critical patent/CA2342773A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
CA002342773A 1998-09-18 1999-09-16 Interferon-epsilon Abandoned CA2342773A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15706898A 1998-09-18 1998-09-18
US09/157,068 1998-09-18
US24529399A 1999-02-05 1999-02-05
US09/245,293 1999-02-05
US35023299A 1999-07-08 1999-07-08
US09/350,232 1999-07-08
PCT/US1999/021279 WO2000017361A2 (en) 1998-09-18 1999-09-16 Interferon-epsilon

Publications (1)

Publication Number Publication Date
CA2342773A1 true CA2342773A1 (en) 2000-03-30

Family

ID=27387961

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002342773A Abandoned CA2342773A1 (en) 1998-09-18 1999-09-16 Interferon-epsilon

Country Status (6)

Country Link
EP (1) EP1141296A2 (de)
JP (1) JP2002526078A (de)
AU (1) AU6042599A (de)
CA (1) CA2342773A1 (de)
IL (1) IL142061A0 (de)
WO (1) WO2000017361A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
CN103520735B (zh) 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
MX2007007591A (es) 2004-12-22 2007-07-25 Ambrx Inc Metodos para expresion y purificacion de hormona de crecimiento humano recombinante.
JP2008525473A (ja) 2004-12-22 2008-07-17 アンブレツクス・インコーポレイテツド 修飾されたヒト成長ホルモン
WO2011153590A1 (en) * 2010-06-09 2011-12-15 Monash University Use of interferon epsilon in methods of diagnosis and treatment
JP2020506923A (ja) * 2017-01-30 2020-03-05 ハドソン インスティテュート オブ メディカル リサーチ 治療方法
CN111420033A (zh) * 2020-03-30 2020-07-17 温州肯恩大学(Wenzhou-KeanUniversity) 人干扰素 -ε在肿瘤治疗中的应用
WO2023183528A2 (en) * 2022-03-24 2023-09-28 Memorial Sloan-Kettering Cancer Center Compositions including ifne and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4614651A (en) * 1981-07-12 1986-09-30 Damon Biotech, Inc. Interferon epsilon
NO832517L (no) * 1982-07-12 1984-01-13 Damon Biotech Inc Interferonpreparat, samt fremgangsmaate for dets fremstilling
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon

Also Published As

Publication number Publication date
JP2002526078A (ja) 2002-08-20
EP1141296A2 (de) 2001-10-10
AU6042599A (en) 2000-04-10
WO2000017361A3 (en) 2001-07-26
WO2000017361A2 (en) 2000-03-30
IL142061A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
EP1860188B1 (de) Menschliches Rezeptor für Zytokine
US6548056B2 (en) Murine interferon-α
CA2342773A1 (en) Interferon-epsilon
US6329175B1 (en) Interferon-ε
AU4825000A (en) Autotaxin variants and uses to treat diseases of metabolism
WO2000055324A1 (en) Murine interferon-alpha named also zcyto13
US20030017980A1 (en) Mammalian Wnt polypeptide-5
US20030175897A1 (en) Human interferon, Zinf2
AU2002324476A8 (en) Human cytokine receptor
WO2002004519A2 (en) Murine cytokine receptor
CA2358873A1 (en) Human polypeptide having multiple epidermal growth factor (egf) -like domains, zntr2
MXPA01002817A (es) Interferon - epsilon
EP1117793A2 (de) Sekretorisches protein - zsig48
US20020132996A1 (en) Secretory protein-48
CA2360577A1 (en) Zlrr3: a human leucine-rich repeat protein
US20020151013A1 (en) Zalpha13: a human secreted protein
US20020142396A1 (en) Mammalian cystatin-8 and its use to inhibit cancer procoagulant protein
CA2393527A1 (en) Educational kit and method using tumor necrosis factor-stimulated gene and protein
EP1326979A2 (de) Menschliches zyklisches nukleotid bindendes protein
WO2000063378A2 (en) Zalpha13: a human secreted protein

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090521